Crystalline Glucosamine Sulfate in the Treatment of Osteoarthritis: Evidence of Long-Term Cardiovascular Safety from Clinical Trials

Table 5: Fasting Plasma Glucose (Expressed as mg/dL) During the GUIDE Study

Evaluation Time	Study Treatment	Baseline Values^*	Values at Each Time Point	Delta at Each Time Point
Baseline	Placebo (n=100)	99 (14)	-	-
Baseline	CGS (n=98)	98 (15)	-	-
Month 3	Placebo (n=82)	99 (15)	101 (16)	2 (9)
Month 3	CGS (n=77)	97 (15)	97 (15)	0 (9)
Month 6	Placebo (n=74)	99 (15)	102 (16)	3 (10)
Month 6	CGS (n=76)	98 (15)	98 (15)	0 (9)

Values are expressed as mean (SD); p=not significant in all comparisons.

^* In this column, the average of absolute values at baseline for the patients still in study at each time point is given.

CGS=crystalline glucosamine sulfate.